These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19949796)

  • 41. Novel approaches to imatinib- and sunitinib-resistant GIST.
    Reichardt P
    Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
    Sawaki A; Nishida T; Doi T; Yamada Y; Komatsu Y; Kanda T; Kakeji Y; Onozawa Y; Yamasaki M; Ohtsu A
    Cancer; 2011 Oct; 117(20):4633-41. PubMed ID: 21456006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
    Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [KIT and KIT: from biology to clinical use].
    Curtit E; Mansi L; Viel E; Dobi E; Chaigneau L; Nguyen T; Pivot X; Blay JY; Kalbacher E
    Bull Cancer; 2012 Feb; 99(2):191-7. PubMed ID: 21669561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gastrointestinal stromal tumor and its targeted therapeutics.
    Dupart J; Zhang W; Trent JC
    Chin J Cancer; 2011 May; 30(5):303-14. PubMed ID: 21527063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
    Montemurro M; Bauer S
    Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
    Gajiwala KS; Wu JC; Christensen J; Deshmukh GD; Diehl W; DiNitto JP; English JM; Greig MJ; He YA; Jacques SL; Lunney EA; McTigue M; Molina D; Quenzer T; Wells PA; Yu X; Zhang Y; Zou A; Emmett MR; Marshall AG; Zhang HM; Demetri GD
    Proc Natl Acad Sci U S A; 2009 Feb; 106(5):1542-7. PubMed ID: 19164557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gastrointestinal stromal tumor: advances in diagnosis and management.
    Patil DT; Rubin BP
    Arch Pathol Lab Med; 2011 Oct; 135(10):1298-310. PubMed ID: 21970485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
    Murray M; Hatcher H; Jessop F; Williams D; Carroll N; Bulusu R; Judson I
    Pediatr Blood Cancer; 2008 Feb; 50(2):386-8. PubMed ID: 17729245
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current and emerging pharmacological treatments for gastrointestinal stromal tumour.
    Ganjoo KN; Patel S
    Drugs; 2011 Feb; 71(3):321-30. PubMed ID: 21319869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.
    Lee JL; Kim JY; Ryu MH; Kang HJ; Chang HM; Kim TW; Lee H; Park JH; Kim HC; Kim JS; Kang YK
    Dig Dis Sci; 2006 Jun; 51(6):1043-6. PubMed ID: 16865565
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical implications of KIT and PDGFRA genotyping in GIST.
    Martín-Broto J; Rubio L; Alemany R; López-Guerrero JA
    Clin Transl Oncol; 2010 Oct; 12(10):670-6. PubMed ID: 20947481
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?
    Nilsson B; Nilsson O; Ahlman H
    Expert Opin Investig Drugs; 2009 Apr; 18(4):457-68. PubMed ID: 19335275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.
    Svetlichnaya J; Huyck TK; Wayne JD; Agulnik M
    Chemotherapy; 2012; 58(1):30-3. PubMed ID: 22415035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.
    Wozniak A; Floris G; Debiec-Rychter M; Sciot R; Schöffski P
    Cancer Invest; 2010 Oct; 28(8):839-48. PubMed ID: 20690803
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
    Reichardt P; Reichardt A
    Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.